Description

Modelis is a Montreal-based biotech company doing drug discovery differently, looking for therapies for rare disorders where no one is looking. At Modelis’ core is its target discovery platform, at the intersection of in vivo biology and machine learning, aiming to decomplexify biology to uncover mechanistic insights into disease pathologies, and leverage them into better, more efficient therapies. Our goal is to be building the premier engine for biological discoveries into rare disorders, unlocking entire segments of this largely untouched market, and enabling better drug discovery, faster. The company's lead program seeks to develop a disease-modifying, first in class therapy for Cori disease, a rare glycogen storage disorder with an unmet medical need.